

Frizzled-7 is required for *Xenopus* heart development

Muhammad Abu-Elmagd^{1,2*}, Joanna Mulvaney^{2*1}, Grant N. Wheeler^{2\$}

¹Center of Excellence in Genomic Medicine Research, King Abdulaziz University, P.O. Box 80216 Jeddah 21589, Kingdom of Saudi Arabia

²School of Biological Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK

*Authors contributed equally to this work

\$Author for correspondence:

Grant N Wheeler, Ph.D.

E-mail address: grant.wheeler@uea.ac.uk

Address: University of East Anglia, School of Biological Sciences, NR4 7TJ, Norwich, UK

Tel.: +44 (0) 1603 59 3988/3245

Fax: +44 (0) 1603 59 2250

E-mail addresses:

Muhammad Abu-Elmagd: mabuelmagd@kau.edu.sa

Joanna Mulvaney: jfm30@sri.utoronto.ca

¹**Present Address:** Sunnybrook Research Institute, 2075 Bayview Ave, Toronto, Canada

Key words: *Xenopus laevis*, cardiogenesis, Wnt signalling, frizzled-7, fzd7

Summary Statement

Wnt signalling has been shown to be important in heart development. Here, we demonstrate that the wnt receptor Fzd7 is required in mediating these Wnt signals.

Abstract

Wnt signalling regulates cardiogenesis during specification of heart tissue and the morphogenetic movements necessary to form the linear heart. Wnt11 mediated non-canonical signalling promotes early cardiac development whilst Wnt11-R, which is expressed later, also signals through the non-canonical pathway to promote heart development. It is unclear which Frizzleds mediate these interactions. Frizzled-7 (*fzd7*) is expressed during gastrulation in the mesodermal cells fated to become heart and then in the primary heart field. This expression is complementary to the expression of *wnt11* and *wnt11-R*. We further show co-localisation of *fzd7* with other early and late heart-specific markers using double *in situ* hybridisation. We have used loss of function analysis to determine the role of *fzd7* during heart development. Morpholino antisense oligonucleotide-mediated knockdown of Fzd7 results in effects on heart development, similar to that caused by Wnt11 loss of function. Surprisingly, overexpression of dominant-negative Fzd7 cysteine rich domain (Fzd7 CRD) results in a cardia bifida phenotype, similar to the loss of *wnt11-R* phenotype. Overexpression of Fzd7 and activation of non-canonical wnt signalling can rescue the effect of Fzd7 CRD. We propose that Fzd7 has an important role during *Xenopus* heart development.

Introduction

During embryogenesis, the heart is one of the first organs to form. Development of the heart includes specification of cardiac progenitors and formation of the linear heart tube by cell migration and morphogenetic movements (Mohun et al., 2000). In *Xenopus*, the heart begins to form during early gastrula stages when the cardiac progenitors arise in the dorsolateral mesoderm. Cell movements during gastrulation result in the dorso-anterior translocation of these regions and subsequent ventral migration during neurulation. The heart progenitors, which comprise cells fated to become primary or secondary heart field, form a linear heart tube at the ventral midline before looping and remodelling to form the beating heart (Kriegmair et al., 2013). Understanding the processes underlying heart development and morphogenesis are important for understanding congenital heart disease.

Heart formation is controlled by many signalling pathways including wnt signalling. Wnt6, 11, and 11-R have all been implicated in *Xenopus* heart development (Garriock et al., 2005; Gessert et al., 2008; Lavery et al., 2008a; Pandur et al., 2002). Wnt antagonists such as Dickkopf-1, Crescent and Sfrp1 have also been reported to control early heart formation (David et al., 2008; Foley and Mercola, 2005; Gibb et al., 2013; Marvin et al., 2001; Schneider and Mercola, 2001). Little is known however about which frizzleds mediate these signals. Frizzled-7 (Fzd7) has been well characterised in *Xenopus laevis* and other species. It has been shown to be involved in numerous developmental processes as well as being shown to be active in several forms of cancer (Huang and Klein, 2004; Liu et al., 2016; Schiffgens et al., 2016; Xu et al., 2016). Fzd7 has been demonstrated to interact with several wnts including Wnt5a (animal cap elongation assays), Wnt6 (in somite development), Wnt8 (co-immunoprecipitation assays, *Xenopus* axis duplication) and Wnt11 (gastrulation movements, neural crest development)(Hsieh et al., 1999; Linker et al., 2005; Medina et al., 2000; Medina and Steinbeisser, 2000; Umbhauer et al., 2000; Witzel et al., 2006). It has also been shown to genetically interact with the co-receptors *ror2* and *ryk* (Hikasa et al., 2002; Kim et al., 2008). *Xenopus* Fzd7 has been implicated in gastrulation movements, tissue separation, and neural crest induction (Abu-Elmagd et al., 2006; Djiane et al., 2000; Wheeler et al., 2000; Winklbauer et al., 2001). We have previously shown *fzd7* to be expressed in the cardiac region throughout development (Wheeler and Hoppler, 1999). It has also been shown that specific depletion of *fzd7* function in *Xenopus* foregut lead to impaired cardiac morphogenesis but no effect on heart specification (Zhang et al., 2013). Here, we further characterise its expression

relative to known heart markers and then use whole-embryo experiments to show that *fzd7* is required for heart formation during early embryonic development.

Results

1. *fzd7* expression overlaps with early heart markers

Expression pattern analysis shows *Xenopus fzd7* is expressed in the heart forming regions throughout development (Wheeler and Hoppler, 1999). At stage 10.5 *fzd7* is expressed in the dorsal mesoderm from which cardiac tissue originates (Wheeler and Hoppler, 1999) and Fig. 1A). As development progresses, *fzd7* expression at stage 25 is maintained in the presumptive cardiac mesoderm as it migrates dorso-laterally to the ventral midline (Fig. 1C-Cii). By stage 29, *fzd7* is expressed throughout the cardiac crescent in the cardiac mesoderm (Fig. 1E, Ei). *fzd7* expression correlates with that of *wnt11* (Fig. 1B, stage 10.5) where expression of both genes seem to be complementary in the presumptive heart region in the dorsal side of the embryo. *fzd7* expression also correlates to that of *wnt11-R* (Fig. 1D-Dii, F, Fi, stages 25 and 29) where it is expressed in the anterior endoderm at stage 25 when *fzd7* is expressed in the heart field. By stage 29 the expression of *fzd7* and *wnt11-R* overlaps (Fig. 1E-Fi). As the heart continues to form, *fzd7* is strongly expressed in the lateral plates of mesoderm, cardiac mesoderm, myocardium and over time, is restricted to the pericardium (Wheeler and Hoppler, 1999), Fig. 2A-Aii, Bii, Cii and Dii). Using double *in situ* hybridisation, we analysed *fzd7* expression in correlation to that of early heart markers including *nkx2-5*, troponin-ic (*tnnic*) and *gata6*, which are all known to be required for *Xenopus* cardiogenesis (Afouda and Hoppler, 2011; Afouda et al., 2008; Drysdale et al., 1994; Flaherty and Dawn, 2008; Fu et al., 1998; Garriock et al., 2005; Jiang and Evans, 1996; Martin et al., 2010). *fzd7* expression overlaps with that of *nkx-2.5* (Fig. 2B-Bii), *tnnic* (Fig. 2C-Cii) and *gata6* (Fig. 2D-Dii) in the forming heart. Interestingly, none of these markers are seen in the pericardium except for *fzd7* (Fig. 2Aii, Bii, Cii, Dii).

2. *fzd7* is required for heart induction or specification

Microinjection into *Xenopus* embryo dorsal blastomeres at the 4 or 8 cell stage targets prospective mesoderm including cardiac tissue. In order to test the role of *fzd7* in heart development, we inhibited its function by injecting either *fzd7* morpholino (*fzd7* MO) or its dominant negative form expressing only the extracellular domain (cysteine

rich domain, *fzd7* CRD), which would disrupt Fzd7 mediated signalling (Abu-Elmagd et al., 2006).

Microinjection of *fzd7* MO into the dorsal blastomeres of 4 or 8 cell embryos leads to a reduction of both early cardiac marker *nkx2-5* (Fig. 3B-Bii) and later cardiac marker *tnnic* expression (Fig. 3E-Eii). Adding increasing amounts of *fzd7* MO leads to a progressively more severe phenotype with a greater number of embryos affected (Fig. 3C). *In situ* hybridisation for *nkx2-5* and *tnnic* show embryos with mild convergent extension phenotypes (Fig. 3B, E) but a severe decrease in cardiac gene expression (Fig. 3Bi and Ei while control morpholino (CMO) show normal heart (Fig. 3A, Ai and D, Di). Some embryos also showed anterior defects (not shown). Sections through the cardiac region showed not only a decrease of *nkx2-5* and *tnnic* expression, but an absence of recognisable heart structures (Fig. 3Bii and 3Eii) compared to CMO (Fig. 3Aii and Dii). The number of embryos injected with *fzd7* MO which showed heart and/or convergent extension and anterior defects are shown in Table S1.

Overexpression of *fzd7* full length (*fzd7* FL) results in severe convergent extension defects, but no cardiac phenotype (Fig. S1A and B). Knockdown with *fzd7* MO can also cause a mild convergent extension phenotype and anterior defects (Abu-Elmagd et al., 2006). In order to test whether this cardiac effect is specific to *fzd7*, we rescued the *fzd7* MO cardiac phenotype with *fzd7* full-length that has been mutated to not bind the *fzd7* MO (*fzd7*SDM as described in (Abu-Elmagd et al., 2006)). Titrating increasing amounts of *fzd7*SDM capped RNA from 250 pg to 1 ng results in a modest rescue of the cardiac phenotype (Fig. 3F, Fi and Table S2), thus showing that *fzd7* is required for normal heart development.

Interestingly, injecting *fzd7* full length at 8-cell stage embryos shows detectable expression of *tnnic* and *nkx2-5* despite some of these embryos showing severe convergent extension movements phenotype (head arrows in Fig. S1A and B). This leads to the suggestion that heart phenotypes are not necessarily due to convergent extension secondary effects.

3. *Fzd7* CRD mimics *wnt11R* morpholino cardia bifida phenotype and is required for non-canonical signalling

To further look at the effect of inhibiting Fzd7 function we took a dominant negative approach using *fzd7* CRD. Surprisingly this did not give a similar result to the MO knockdown. Instead, increasing amounts of *fzd7* CRD results in a dose dependent

increase in frequency and severity of cardia bifida. This was very similar to the phenotype seen for *wnt-11R* knockdown (Garriock et al., 2005). Embryos with very mild convergent extension movement defects displayed a severe cardia bifida phenotype as shown by *tnnic* (Fig. 4B-Bii and C) and *nkx2-5* (Fig. 4G, Gi) expression. Control embryos showed normal expression of *tnnic* (Fig. 4A-Aii) and *nkx2-5* (Fig. 4F, Fi). These results suggest that the cardia bifida phenotype is not a secondary effect of the convergent extension defect. Overexpression of *fzd7* FL gives a severe convergent extension phenotype but no cardiac phenotype (Fig. S1A and B). Embryos with cardia bifida were unable to recover and form a normal heart when incubated up to stage 41 (n= 23, data not shown). Embryos injected with a dominant negative form of *fzd3* (*fzd3* CRD) into the dorsal blastomeres at 4 cell stage did not show cardia bifida (n= 27, Fig. 4E, Ei) indicating that the cardia bifida phenotype is specific to *fzd7* CRD. Furthermore, this phenotypic specificity to *fzd7* CRD was confirmed by rescuing the cardia bifida with full length *fzd7* capped RNA (Fig. 5A-D and F).

It has been previously reported that a Jun N-terminal kinases (Jun) inhibitor phenocopies the *wnt11-R* cardiac phenotype of effects on cardiac morphogenesis and heart tube fusion, suggesting signalling through the non-canonical pathway (Garriock et al., 2005; Gessert et al., 2008). We therefore determined to rescue the *fzd7* CRD phenotype with Dishevelled1-Delta-N (*dv11ΔN*) capped RNA. *Dv11ΔN* capped RNA can rescue *fzd7* CRD (Fig. 5E, Ei and G, Gi and Table S3) suggesting that *fzd7* is required for non-canonical wnt signalling during heart development.

Discussion

Wnt signalling through the canonical and non-canonical pathways has been implicated in many aspects of heart development (Gessert and Kuhl, 2010; Ruiz-Villalba et al., 2016). How the wnt signals that arise from both non-cardiogenic and cardiogenic tissue are integrated into heart development is less well understood. Frizzled receptors are only a part of the increasingly complicated wnt-receptor complex found at the cell membrane which can also include Lrp5/6, Ror2, Ryk and Kremen (Bryja et al., 2009; Korol et al., 2008; Mazzotta et al., 2016; van Wijk et al., 2009); however, Frizzleds are critical components of the Wnt receptor complex and so understanding their role in heart development is necessary to fully understand the signalling involved. We have previously shown that *fzd7* is expressed throughout heart development and in this study, we show that it is functionally required in both early and late heart development.

Morpholino knockdown of Fzd7 leads to effects on heart development including in some cases a complete loss of heart (Fig. 3). Overexpression of Fzd7 gives rise to convergent extension defects as previously reported (Abu-Elmagd et al., 2006; Sumanas and Ekker, 2001; Winklbauer et al., 2001) but does not affect heart development. We can rescue the *fzd7* MO phenotype by co-injecting site directed mutagenized full length *fzd7* (Fig. 3). These results suggest *fzd7* is required for initial heart development though we cannot exclude the possibility that it may also be playing a more general role in dorsoventral mesoderm patterning. Fzd7 could be interacting with Wnt11 (Kim et al., 2008; Tao et al., 2005; Witzel et al., 2006) or another wnt ligand such as Wnt3a (Mazzotta et al., 2016), Wnt6 (Gibb et al., 2013; Lavery et al., 2008a; Lavery et al., 2008b) or Wnt8c (Ruiz-Villalba et al., 2016; Schneider and Mercola, 2001) during these stages of development.

As suggested, it is possible that the *fzd7* morphant cardiac phenotype is a secondary effect of failures in mesoderm specification, patterning, gastrulation, axis formation and tissue separation. We have made efforts to inject embryos at the 4 and 8 cell stages to give as small a convergent extension phenotype as possible to generate normal looking embryos but with clear heart phenotypes. The results suggest that the effect of Fzd7 during early heart development is not secondary to convergent extension defects or mesoderm development, however, this cannot be ruled out completely (Fig. 3).

An interesting feature of the loss of function analysis using *fzd7* morpholino and a dominant negative *fzd7* CRD, is that they give different cardiac phenotypes. *fzd7* morphants have anterior defects, convergent extension defects and reduction in *nkx2-5* expression, whereas *fzd7* CRD capped RNA injections result in embryos with convergent extension defects and cardia bifida but no head defects or loss of cardiac markers. Interestingly it has been shown that the only way to replicate the anterior defect phenotype with a *fzd7* CRD construct is to inject the capped RNA into oocytes (Medina et al., 2000). This could be because the relevant signalling event has been completed by time the product of mRNA injected at the 4 or 8 cell stage has been generated. It is possible that if we injected oocytes with *fzd7* CRD then we might find embryos showing loss of the heart. Another possibility is that the Morpholino is able to disrupt all Wnt signalling through *fzd7* by preventing translation of Fzd7 protein, but *fzd7* CRD only disrupts non-canonical signalling in this context. The requirement for co-receptors in canonical signalling may allow the CRD to interact with endogenous Fzd7 and any Lrps present allowing the receptor complex aggregates to form. In

addition to this, it has been shown to be possible to activate canonical Wnt signalling using CRD constructs (Carron et al., 2003). Perhaps canonical Wnt signalling mediated by Fzd7 early on during development is allowed to proceed by the Fzd7 CRD, but then when Fzd7 switches to mediate non-canonical signalling, the CRD starts to behave as a dominant negative. Other possibilities are that the Morpholino may have a broader specificity than thought or that the injected RNA of the *fzd7* CRD construct may not be very stable and thus only provide a short term effect compared to the Morpholino. These options remain to be tested further.

The *fzd7* CRD phenotype is very similar to the *wnt11-R* Morpholino phenotype (Garriock et al., 2005). It has previously been shown that *DM-GRASP/alcam* expression lies downstream of *wnt11-R* signalling and that *DM-GRASP/alcam* can mediate non-canonical wnt signalling effects on morphogenetic movements involved in the developing heart. The *DM-GRASP/alcam* morpholino phenotype is also similar to the *fzd7* CRD phenotype in that they both lead to a cardia bifida like phenotype and a thickening of the myocardium. This suggests Fzd7 could be mediating the Wnt11-R control of *DM-GRASP/alcam* expression. This needs to be investigated further.

Ruiz-Villalba and colleagues (Ruiz-Villalba et al., 2016) suggest a model where periodic switching between proliferation and differentiation within the developing heart is mediated by the periodic and reciprocal activity of the canonical and non-canonical wnt pathways. *fzd7* could be playing a crucial role in this process depending upon the Wnts and other receptors expressed at specific times.

In conclusion, we have shown *fzd7* to be involved in heart development. Further investigation is required to determine the specific wnt(s) it is interacting with at different stages of heart development.

Materials and Methods

1. Embryo manipulation

All experiments were performed in compliance with the relevant laws and institutional guidelines at the University of East Anglia. The research was approved by the local ethical review committee according to UK Home Office regulations. *Xenopus laevis* embryos were obtained as previously described (Harrison et al., 2004). Staging of the embryos was carried out according to the normal time table of Nieuwkoop and Faber (Nieuwkoop and Faber, 1994). Embryos at the required stages were fixed in MEMFA, washed in PBS, dehydrated in ascending grades of Methanol/PBS, then

stored in 100% MeOH at -20°C until processing for single or double *in situ* hybridisation.

2. Constructs

fzd7 full-length (*fzd7*-FL) and dominant negative form *fzd7*-cysteine rich domain (*fzd7*-CRD) were sub-cloned into pCS2+ at *Cla1*–*Xho1* restriction sites as described in (Wheeler et al., 2000). *Fzd7* MO titration by RNA in the rescue experiments was avoided by creating a site directed mutagenesis construct of the full coding sequence of *fzd7* (*fzd7* SDM) as described in (Abu-Elmagd et al., 2006). *fzd3* full-length (*fzd3* FL) and *fzd3* CRD were kind gifts from Peter Klein. Dishevelled construct (*Dvl1-Delta-N*) was a gift from Roberto Mayor (De Calisto et al., 2005).

3. *In vitro* capped mRNA synthesis and embryo microinjections

All Capped mRNAs of all genes used for RNA injections were prepared according to the manufacturer's instructions using the SP6 mMessage mMachine Ambion kit (Invitrogen™ AM1340). Anti-sense oligonucleotides, morpholinos (MOs), were obtained and designed by Gene Tools (www. gene-tools.com, Oregon, USA) using the reported sequence for the control morpholino (CMO) (5'-CCTCTTACCTCAgTTACAATTTATA-3') and *fzd7*MO (5'-GCGGAGTGAGCAGAAATCGGCTGA-3')(Sumanas and Ekker, 2001). MOs were diluted, prepared before use according to the manufacturer's instructions and tested using the *in vitro* translation assay (TNT coupled reticulocyte lysate system, Promega-L4600). For targeting the heart, the dorsal blastomeres of the 4 and 8 cell stage embryos were injected as previously described (Lavery et al., 2008a). Capped mRNA and MOs were co-injected with *lac-Z* for lineage tracing. Each experiment was carried out as an internally controlled group. Each experiment was carried out 3 times and the numbers of embryos in each class were pooled.

4. RNA probe synthesis and *in situ* hybridisation

fzd7 in pBluescript was linearised with *Xba1* and transcribed by T7, *nkx2-5* was linearised with *BamH1* and transcribed with T7, *troponin-IC* (*tnnic*) was linearised with *Xho1* and transcribed with T3, *gata6* was linearised with *Xba1* and transcribed with T7. Promega probe synthesis manufacturing instructions were followed with *fzd7* probe labelled with Fluorescence-substituted nucleotide (FI-UTP) and for other heart makers labelled with DIG-substituted nucleotide. Each RNA probe was added to 10ml hybridisation buffer and stored at -20°C for *in situ* hybridisation. Single (Harland, 1991)

or double (Knecht et al., 1995) *in situ* hybridization was carried out as previously described (Abu-Elmagd et al., 2006). Anti-Fluorescein was detected using Fast Red tablets (Kelloff et al., 2006) while anti-Digoxigenin was detected with NBT/BCIP. Frozen sectioning and wax sectioning were carried out as described (Harrison et al., 2004; Hatch et al., 2016). Images were taken using Leica microscope and Axiovision software.

Acknowledgments

The authors would like to thank Stefan Hoppler, Boni Afouda and Andrea Münsterberg as well as members of the Wheeler and Münsterberg labs for many helpful discussions.

Competing Interests

No competing interests declared

Author contributions

Conception and design - GW

Investigation and data acquisition – MAE and JM

Analysis and interpretation of data – GW, MAE and JM

Material support - GW

Writing, review and/or revision of manuscript – GW, MAE and JM

Study supervision - GW

Funding

JM was funded by a BBSRC Studentship. This work was funded by a BBSRC new investigator award to GW (Grant no. G15793).

References

- Abu-Elmagd, M., Garcia-Morales, C., Wheeler, G.N., 2006. Frizzled7 mediates canonical Wnt signaling in neural crest induction. *Dev Biol* 298, 285-298.
- Afouda, B.A., Hoppler, S., 2011. Different requirements for GATA factors in cardiogenesis are mediated by non-canonical Wnt signaling. *Dev Dyn* 240, 649-662.
- Afouda, B.A., Martin, J., Liu, F., Ciau-Uitz, A., Patient, R., Hoppler, S., 2008. GATA transcription factors integrate Wnt signalling during heart development. *Development* 135, 3185-3190.
- Bryja, V., Andersson, E.R., Schambony, A., Esner, M., Bryjova, L., Biris, K.K., Hall, A.C., Kraft, B., Cajanek, L., Yamaguchi, T.P., Buckingham, M., Arenas, E., 2009. The extracellular domain of Lrp5/6 inhibits noncanonical Wnt signaling in vivo. *Mol Biol Cell* 20, 924-936.
- Carron, C., Pascal, A., Djiane, A., Boucaut, J.C., Shi, D.L., Umbhauer, M., 2003. Frizzled receptor dimerization is sufficient to activate the Wnt/beta-catenin pathway. *Journal of cell science* 116, 2541-2550.
- David, R., Brenner, C., Stieber, J., Schwarz, F., Brunner, S., Vollmer, M., Mentele, E., Muller-Hocker, J., Kitajima, S., Lickert, H., Rupp, R., Franz, W.M., 2008. MesP1 drives vertebrate cardiovascular differentiation through Dkk-1-mediated blockade of Wnt-signalling. *Nat Cell Biol* 10, 338-345.
- De Calisto, J., Araya, C., Marchant, L., Riaz, C.F., Mayor, R., 2005. Essential role of non-canonical Wnt signalling in neural crest migration. *Development* 132, 2587-2597.
- Djiane, A., Riou, J., Umbhauer, M., Boucaut, J., Shi, D., 2000. Role of frizzled 7 in the regulation of convergent extension movements during gastrulation in *Xenopus laevis*. *Development* 127, 3091-3100.
- Drysdale, T.A., Tonissen, K.F., Patterson, K.D., Crawford, M.J., Krieg, P.A., 1994. Cardiac troponin I is a heart-specific marker in the *Xenopus* embryo: expression during abnormal heart morphogenesis. *Dev Biol* 165, 432-441.
- Flaherty, M.P., Dawn, B., 2008. Noncanonical Wnt11 signaling and cardiomyogenic differentiation. *Trends Cardiovasc Med* 18, 260-268.
- Foley, A.C., Mercola, M., 2005. Heart induction by Wnt antagonists depends on the homeodomain transcription factor Hex. *Genes & development* 19, 387-396.
- Fu, Y., Yan, W., Mohun, T.J., Evans, S.M., 1998. Vertebrate tinman homologues XNkx2-3 and XNkx2-5 are required for heart formation in a functionally redundant manner. *Development* 125, 4439-4449.
- Garriock, R.J., D'Agostino, S.L., Pilcher, K.C., Krieg, P.A., 2005. Wnt11-R, a protein closely related to mammalian Wnt11, is required for heart morphogenesis in *Xenopus*. *Dev Biol* 279, 179-192.
- Gessert, S., Kuhl, M., 2010. The multiple phases and faces of wnt signaling during cardiac differentiation and development. *Circ Res* 107, 186-199.

Gessert, S., Maurus, D., Brade, T., Walther, P., Pandur, P., Kuhl, M., 2008. DM-GRASP/ALCAM/CD166 is required for cardiac morphogenesis and maintenance of cardiac identity in first heart field derived cells. *Dev Biol* 321, 150-161.

Gibb, N., Lavery, D.L., Hoppler, S., 2013. *sfrp1* promotes cardiomyocyte differentiation in *Xenopus* via negative-feedback regulation of Wnt signalling. *Development* 140, 1537-1549.

Harland, R.M., 1991. In situ hybridization: an improved whole-mount method for *Xenopus* embryos. *Methods in cell biology* 36, 685-695.

Harrison, M., Abu-Elmagd, M., Grocott, T., Yates, C., Gavrilovic, J., Wheeler, G.N., 2004. Matrix metalloproteinase genes in *Xenopus* development. *Dev Dyn* 231, 214-220.

Hatch, V.L., Marin-Barba, M., Moxon, S., Ford, C.T., Ward, N.J., Tomlinson, M.L., Desanlis, I., Hendry, A.E., Hontelez, S., van Kruijsbergen, I., Veenstra, G.J., Munsterberg, A.E., Wheeler, G.N., 2016. The positive transcriptional elongation factor (P-TEFb) is required for neural crest specification. *Dev Biol* 416, 361-372.

Hikasa, H., Shibata, M., Hiratani, I., Taira, M., 2002. The *Xenopus* receptor tyrosine kinase *Xror2* modulates morphogenetic movements of the axial mesoderm and neuroectoderm via Wnt signaling. *Development* 129, 5227-5239.

Hsieh, J.C., Rattner, A., Smallwood, P.M., Nathans, J., 1999. Biochemical characterization of Wnt-frizzled interactions using a soluble, biologically active vertebrate Wnt protein. *Proceedings of the National Academy of Sciences of the United States of America* 96, 3546-3551.

Huang, H.C., Klein, P.S., 2004. The Frizzled family: receptors for multiple signal transduction pathways. *Genome Biol* 5, 234.

Jiang, Y., Evans, T., 1996. The *Xenopus* GATA-4/5/6 genes are associated with cardiac specification and can regulate cardiac-specific transcription during embryogenesis. *Dev Biol* 174, 258-270.

Kelloff, G.J., Lippman, S.M., Dannenberg, A.J., Sigman, C.C., Pearce, H.L., Reid, B.J., Szabo, E., Jordan, V.C., Spitz, M.R., Mills, G.B., Papadimitrakopoulou, V.A., Lotan, R., Aggarwal, B.B., Bresalier, R.S., Kim, J., Arun, B., Lu, K.H., Thomas, M.E., Rhodes, H.E., Brewer, M.A., Follen, M., Shin, D.M., Parnes, H.L., Siegfried, J.M., Evans, A.A., Blot, W.J., Chow, W.H., Blount, P.L., Maley, C.C., Wang, K.K., Lam, S., Lee, J.J., Dubinett, S.M., Engstrom, P.F., Meyskens, F.L., Jr., O'Shaughnessy, J., Hawk, E.T., Levin, B., Nelson, W.G., Hong, W.K., 2006. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. *Clinical cancer research : an official journal of the American Association for Cancer Research* 12, 3661-3697.

Kim, G.H., Her, J.H., Han, J.K., 2008. *Ryk* cooperates with Frizzled 7 to promote Wnt11-mediated endocytosis and is essential for *Xenopus laevis* convergent extension movements. *The Journal of cell biology* 182, 1073-1082.

Knecht, A.K., Good, P.J., Dawid, I.B., Harland, R.M., 1995. Dorsal-ventral patterning and differentiation of *noggin*-induced neural tissue in the absence of mesoderm. *Development* 121, 1927-1935.

- Korol, O., Gupta, R.W., Mercola, M., 2008. A novel activity of the Dickkopf-1 amino terminal domain promotes axial and heart development independently of canonical Wnt inhibition. *Dev Biol* 324, 131-138.
- Kriegmair, M.C., Frenz, S., Dusl, M., Franz, W.M., David, R., Rupp, R.A., 2013. Cardiac differentiation in *Xenopus* is initiated by mespa. *Cardiovasc Res* 97, 454-463.
- Lavery, D.L., Davenport, I.R., Turnbull, Y.D., Wheeler, G.N., Hoppler, S., 2008a. Wnt6 expression in epidermis and epithelial tissues during *Xenopus* organogenesis. *Dev Dyn* 237, 768-779.
- Lavery, D.L., Martin, J., Turnbull, Y.D., Hoppler, S., 2008b. Wnt6 signaling regulates heart muscle development during organogenesis. *Developmental biology* 323, 177-188.
- Linker, C., Lesbros, C., Gros, J., Burrus, L.W., Rawls, A., Marcelle, C., 2005. beta-Catenin-dependent Wnt signalling controls the epithelial organisation of somites through the activation of paraxis. *Development* 132, 3895-3905.
- Liu, N., Zang, S., Liu, Y., Wang, Y., Li, W., Liu, Q., Ji, M., Ma, D., Ji, C., 2016. FZD7 regulates BMSCs-mediated protection of CML cells. *Oncotarget* 7, 6175-6187.
- Martin, J., Afouda, B.A., Hoppler, S., 2010. Wnt/beta-catenin signalling regulates cardiomyogenesis via GATA transcription factors. *Journal of anatomy* 216, 92-107.
- Marvin, M.J., Di Rocco, G., Gardiner, A., Bush, S.M., Lassar, A.B., 2001. Inhibition of Wnt activity induces heart formation from posterior mesoderm. *Genes & development* 15, 316-327.
- Mazzotta, S., Neves, C., Bonner, R.J., Bernardo, A.S., Docherty, K., Hoppler, S., 2016. Distinctive Roles of Canonical and Noncanonical Wnt Signaling in Human Embryonic Cardiomyocyte Development. *Stem Cell Reports* 7, 764-776.
- Medina, A., Reintsch, W., Steinbeisser, H., 2000. *Xenopus* frizzled 7 can act in canonical and non-canonical Wnt signaling pathways: implications on early patterning and morphogenesis. *Mech Dev* 92, 227-237.
- Medina, A., Steinbeisser, H., 2000. Interaction of Frizzled 7 and Dishevelled in *Xenopus*. *Dev Dyn* 218, 671-680.
- Mohun, T.J., Leong, L.M., Weninger, W.J., Sparrow, D.B., 2000. The morphology of heart development in *Xenopus laevis*. *Dev Biol* 218, 74-88.
- Nieuwkoop, P., Faber, J., 1994. Normal Table of *Xenopus laevis* (Daudin)(Garland, New York). ISBN 0-8153-1896-0.
- Pandur, P., Läsche, M., Eisenberg, L.M., Kühl, M., 2002. Wnt-11 activation of a non-canonical Wnt signalling pathway is required for cardiogenesis. *Nature* 418, 636-641.
- Ruiz-Villalba, A., Hoppler, S., van den Hoff, M.J., 2016. Wnt signaling in the heart fields: Variations on a common theme. *Dev Dyn* 245, 294-306.
- Schiffgens, S., Wilkens, L., Brandes, A.A., Meier, T., Franceschi, E., Ermani, M., Hartmann, C., Sandalcioglu, I.E., Dumitru, C.A., 2016. Sex-specific clinicopathological

significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma. *Oncotarget* 7, 55169-55180.

Schneider, V.A., Mercola, M., 2001. Wnt antagonism initiates cardiogenesis in *Xenopus laevis*. *Genes & development* 15, 304-315.

Sumanas, S., Ekker, S.C., 2001. *Xenopus* frizzled-7 morphant displays defects in dorsoventral patterning and convergent extension movements during gastrulation. *Genesis* 30, 119-122.

Tao, Q., Yokota, C., Puck, H., Kofron, M., Birsoy, B., Yan, D., Asashima, M., Wylie, C.C., Lin, X., Heasman, J., 2005. Maternal wnt11 activates the canonical wnt signaling pathway required for axis formation in *Xenopus* embryos. *Cell* 120, 857-871.

Umbhauer, M., Djiane, A., Goisset, C., Penzo-Mendez, A., Riou, J.F., Boucaut, J.C., Shi, D.L., 2000. The C-terminal cytoplasmic Lys-thr-X-X-X-Trp motif in frizzled receptors mediates Wnt/beta-catenin signalling. *Embo j* 19, 4944-4954.

van Wijk, N.V., Witte, F., Feike, A.C., Schambony, A., Birchmeier, W., Mundlos, S., Stricker, S., 2009. The LIM domain protein Wtip interacts with the receptor tyrosine kinase Ror2 and inhibits canonical Wnt signalling. *Biochem Biophys Res Commun* 390, 211-216.

Wheeler, G.N., Hamilton, F.S., Hoppler, S., 2000. Inducible gene expression in transgenic *Xenopus* embryos. *Curr Biol* 10, 849-852.

Wheeler, G.N., Hoppler, S., 1999. Two novel *Xenopus* frizzled genes expressed in developing heart and brain. *Mechanisms of development* 86, 203-207.

Winklbauer, R., Medina, A., Swain, R.K., Steinbeisser, H., 2001. Frizzled-7 signalling controls tissue separation during *Xenopus* gastrulation. *Nature* 413, 856-860.

Witzel, S., Zimyanin, V., Carreira-Barbosa, F., Tada, M., Heisenberg, C.P., 2006. Wnt11 controls cell contact persistence by local accumulation of Frizzled 7 at the plasma membrane. *The Journal of cell biology* 175, 791-802.

Xu, R., Zeng, S., Xie, W., Sun, C., Chen, Y.L., Chen, M.J., Zhang, L., 2016. The expression and function of Frizzled-7 in human renal cell carcinoma. *Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico* 18, 269-276.

Zhang, Z., Rankin, S.A., Zorn, A.M., 2013. Different thresholds of Wnt-Frizzled 7 signaling coordinate proliferation, morphogenesis and fate of endoderm progenitor cells. *Dev Biol* 378, 1-12.

Figures




Figure 1:

Endogenous expression of *fzd7* in *Xenopus* heart and relative to *wnt11* and *wnt11-R* expression. (A, B): stage 10.5 (mid-gastrula) *fzd7* and *wnt11* expression detected at the dorsal side of the embryo and appear complementary in the presumptive heart region. (C-Cii and D-Di): *fzd7* and *wnt11-R* expression at stage 25. *fzd7* is seen in the heart field and *wnt11-R* in the anterior endoderm. *fzd7* and *wnt11-R* expression are complementary in the heart region (Cii, Dii). (E, Ei and F, Fi): stage 29 embryos with *fzd7* and *wnt11-R* expression in the heart field. hf: heart field, ae: anterior endoderm. Magnification 20x.




Figure 2:

***fzd7* expression coincides with expression of the early heart markers *nkx2-5*, *tnnic* and *gata6*.** Lateral view of *Xenopus laevis* embryos at stage 31 showing *fzd7* expression detected in red (A-Aii) and co-localised by double *in situ* hybridisation with other heart markers in dark blue including *nkx2-5* (B-Bii), *tnnic* (C-Cii) and *gata6* (D-Dii). (Ai, Bi, Ci, Di). Magnified lateral view of the same embryos in (A, B, C and D) respectively. (Aii, Bii, Cii, Dii). Cross section through the heart region of the embryos in (A, B, C, D) respectively. *fzd7* is expressed in the myocardium and pericardium (Aii) and in other structures including neural crest, eye, pronephric duct and tail bud. *fzd7* expression shows a high degree of overlapping with the heart markers in the myocardium but not in the pericardium (Bii, Cii, Dii). h: heart, c: cement gland, e: eye, nc: neural crest, pnd: pronephric duct, tb: tail bud, mc: myocardium, lpm: lateral plate

of mesoderm. Magnification: 20x in (A, B, C, D), 30x in (Ai, Bi, Ci, Di), 200x in (Aii, Bii, Cii, Dii).




Figure 3:

Fzd7 is required for Xenopus heart development

(A, Ai and D, Di) Lateral and ventral views of embryos injected in the dorsal blastomeres (DB) at 4 cell stage with control morpholino (CMO) showing normal *nkx2-5* (A-Ai) and *tnnic* (D, Di) expression. (Aii, Dii). Cross sections in the heart region of the embryos in (A) and (D) respectively showing normal *nkx2-5* and *tnnic* expression in the myocardium. (B, Bi and E, Ei). Lateral and ventral views of embryos injected in the DB at 4 cell stage with *fzd7* MO showing loss of *nkx2-5* (B-Bi) and *tnnic* (E, Ei) expression. (Bii, Eii). Cross sections in the heart region of the embryos in (B) and (E) respectively showing loss of the heart. (C) Graph showing that *fzd7* MO phenotype leads to reduction/loss of *nkx2-5* expression in a dose-dependent manner. (F, Fi). *Fzd7* MO phenotype can be rescued by *fzd7* SDM full length, (Fi) is the key for the phenotype scoring. Red staining in B, Bi and Bii is due to *lac-Z* lineage tracing using Red-Gal.




Figure 4:

A dominant negative Fzd7 induces cardia bifida phenotype.

(A-Ai and F, Fi) Lateral and ventral views of wild type embryos at stage 29 showing normal *tnnic* (A, Ai) and *nkx2-5* (F-Fi) expression in the heart. (B, Bi and G, Gi) Lateral and ventral views of embryos injected in the dorsal blastomeres at 4 cell stage with dominant negative *fzd7* (*fzd7* CRD). The cardia bifida phenotype is shown by *tnnic* (B, Bi) and *nkx2-5* (G-Gi) expression. These embryos were fixed at the same stage as the control embryos in (A and F). (C) Graph showing *fzd7* CRD cardia bifida phenotype percentages indicated by *tnnic* expression. (D, Di). Lateral and ventral views of embryos injected in the dorsal blastomeres (DB) at 4 cell stage with full length of *fzd7* showing normal heart tube. Note that embryos in (D) and (G) are showing severe convergent extension defects but cardia bifida phenotype is only induced by *fzd7* CRD. (E, Ei). Lateral and ventral views of injected embryo in the DB at 4 cell stage with *fzd3* dominant negative form (*fzd3* CRD) showing normal heart looping (at stage 38) indicating that *fzd7* CRD cardia bifida phenotype is specific to Fzd7. Magnification 20x.

(H and I). Lateral (H) and ventral (I) views of embryos injected in the DB at 4 cell stage with full length of *fzd7* showing normal heart tube indicated by *nkx2-5* expression.




Figure 5:

Activation of non-canonical wnt signalling rescues *fzd7* CRD induced cardia bifida.

(A, Ai) Wild type control embryos showing normal *tnnic* expression in the heart. (B, Bi) *fzd7* full length overexpression (500pg) injected into the dorsal blastomeres (DB) at the 4 cell stage show normal heart expression of *tnnic* despite suffering a severe extension movement defect. (C). Embryos injected with 500pg *fzd7* CRD show cardia bifida phenotype, note that embryos have normal to mild convergent extension defects. (D). Rescue of the *fzd7* CRD (250pg) cardia bifida phenotype with 250pg full length *fzd7*, embryos show normal morphology as well as *tnnic* expression. (F). Graph of *fzd7* CRD cardia bifida phenotype rescue with *fzd7* Full length. (E, Ei). Rescue of *fzd7* CRD (500pg) cardia bifida phenotype with 1.25ng *dishevelled1-Delta-N* (*Dvl1ΔN*) indicating that *fzd7* is required for the non-canonical signalling in the heart. (G). Graph of *fzd7* CRD cardia bifida phenotype rescue with *dvl1ΔN*, (Gi) is the key for the cardia bifida phenotype scoring in (G). Magnification 20x.

Supplemental Tables and Figures

Table S1:

<i>fzd7</i> MO Injections	Dose (ng)	Total No. of Embryos	Anterior Defects	Reduced Heart	Anterior Defects and reduced Heart	Normal Morphology and reduced Heart	% Anterior Defects	% Reduced Heart	% Anterior Defects and reduced Heart	% Normal Morphology and reduced Heart
DB	20	40	8	1	1	0	20	3	3	0
VB	20	26	2	0	0	0	8	0	0	0
DB	40	43	15	19	15	4	35	44	35	9
VB	40	47	3	0	0	0	6	0	0	0
DB	60	51	49	36	34	2	96	71	67	4
VB	60	66	0	0	0	0	0	0	0	0
DB	70	23	23	23	23	0	100	100	100	0
VB	70	30	5	0	0	0	17	0	0	0

***fzd7* Morpholino dose response.** Increasing amounts of *fzd7* MO were injected at the 4 cell stage into both blastomeres of the dorsal side (DB) of the embryo and ventral side (VB) as a control. Observed phenotypes included a range of convergent extension phenotypes from severe to mild, varying degrees of anterior defects and a reduction of *nkx2-5* or *tnnic* expression.

Table S2:

Embryo injections	Total No. of Embryos	No Heart	Reduced Heart	Normal Heart	% No Heart	% Reduced Heart	% Normal Heart
Non-injected control	76	0	0	76	0	0	100
1ng <i>fzd7</i> SDM 2x DB	80	0	0	80	0	0	100
1ng <i>fzd7</i> SDM 2x VB	79	0	0	79	0	0	100
60ng <i>fzd7</i> MO 2x DB	52	26	15	11	50	29	21
60ng <i>fzd7</i> MO 2x VB	50	1	3	46	2	6	92
60ng <i>fzd7</i> MO + 250pg <i>lacZ</i> 2x DB	93	31	41	21	33	44	23
60ng <i>fzd7</i> MO + 250pg <i>lacZ</i> 2x VB	79	0	0	79	0	0	100
60ng <i>fzd7</i> MO + 500pg <i>lacZ</i> 2x DB	101	40	33	28	40	32	28
60ng <i>fzd7</i> MO + 500pg <i>lacZ</i> 2x VB	89	3	0	86	3	0	97
60ng <i>fzd7</i> MO + 750pg <i>lacZ</i> 2x DB	101	27	53	21	27	52	21
60ng <i>fzd7</i> MO + 750pg <i>lacZ</i> 2x VB	74	0	0	74	0	0	100
60ng <i>fzd7</i> MO + 1ng <i>lacZ</i> 2x DB	115	34	49	32	29	43	28
60ng <i>fzd7</i> MO + 1ng <i>lacZ</i> 2x VB	75	0	1	74	0	1	99
60ng <i>fzd7</i> MO + 250pg <i>fzd7</i> SDM 2x DB	52	17	26	9	33	50	17
60ng <i>fzd7</i> MO + 250pg <i>fzd7</i> SDM 2x VB	53	0	0	53	0	0	100
60ng <i>fzd7</i> MO + 500pg <i>fzd7</i> SDM 2x DB	107	16	42	49	15	39	46
60ng <i>fzd7</i> MO + 500pg <i>fzd7</i> SDM 2x VB	59	0	1	58	0	2	98
60ng <i>fzd7</i> MO + 750pg <i>fzd7</i> SDM 2x DB	100	14	40	46	14	40	46
60ng <i>fzd7</i> MO + 750pg <i>fzd7</i> SDM 2x VB	75	0	1	74	0	1	99
60ng <i>fzd7</i> MO + 1ng <i>fzd7</i> SDM 2x DB	133	20	56	57	15	42	43
60ng <i>fzd7</i> MO + 1ng <i>fzd7</i> SDM 2x VB	107	0	1	106	0	1	99


***fzd7* MO phenotype is rescued by *fzd7* SDM.** Injecting 1ng of *fzd7*SDM capped RNA does not give a cardiac phenotype. Coinjecting 60 ng *fzd7* MO with from 250pg –1ng of *lacZ* capped RNA gives between 51% and 30% embryos with no heart and between 22% and 29% embryos with normal hearts. Coinjecting with *fzd7* SDM capped RNA from 250pg- 1ng gives a dose responsive decrease of embryos with no heart 33% at 250pg to 15% at 1 ng and an increase in embryos with a normal heart from 18% at 250pg to 43% at 1ng. DB: dorsal blastomeres, VB: ventral blastomeres.

Table S3:

Embryo injections	Total No. of Embryos	Severe Cardia Bifida	Mid. Cardia Bifida	Partial Cardia Bifida	Normal Heart	% Severe Cardia Bifida	% Mid. Cardia Bifida	% Partial Cardia Bifida	% Normal Heart
Non-injected control	90	0	0	0	90	0	0	0	100
1.5ng <i>dv1</i> Δ N 2x DB	84	0	0	0	84	0	0	0	100
1.5ng <i>dv1</i> Δ N 2x VB	88	0	0	0	88	0	0	0	100
500pg <i>fzd7</i> CRD + 750pg <i>lacZ</i> 2x DB	92	29	25	23	15	32	27	25	16
500pg <i>fzd7</i> CRD + 750pg <i>lacZ</i> 2x VB	75	0	0	0	75	0	0	0	100
500pg <i>fzd7</i> CRD + 1ng <i>lacZ</i> 2x DB	67	25	10	22	10	37	15	33	15
500pg <i>fzd7</i> CRD + 1ng <i>lacZ</i> 2x VB	62	0	0	0	62	0	0	0	100
500pg <i>fzd7</i> CRD + 1.25ng <i>lacZ</i> 2x DB	81	37	18	17	9	46	22	21	11
500pg <i>fzd7</i> CRD + 1.25ng <i>lacZ</i> 2x VB	84	0	0	0	84	0	0	0	100
500pg <i>fzd7</i> CRD + 1.5ng <i>lacZ</i> 2x DB	37	10	16	8	3	27	43	22	8
500pg <i>fzd7</i> CRD + 1.5ng <i>lacZ</i> 2x VB	28	0	0	0	28	0	0	0	100
500pg <i>fzd7</i> CRD + 750pg <i>dv1</i> Δ N 2x DB	89	21	23	30	15	24	26	33	17
500pg <i>fzd7</i> CRD + 750pg <i>dv1</i> Δ N 2x VB	76	0	0	0	76	0	0	0	100
500pg <i>fzd7</i> CRD + 1ng <i>dv1</i> Δ N 2x DB	91	6	24	34	27	7	26	37	30
500pg <i>fzd7</i> CRD + 1ng <i>dv1</i> Δ N 2x VB	93	0	0	0	93	0	0	0	100
500pg <i>fzd7</i> CRD + 1.25ng <i>dv1</i> Δ N 2x DB	67	8	11	13	35	12	16	19	52
500pg <i>fzd7</i> CRD + 1.25ng <i>dv1</i> Δ N 2x VB	67	0	0	0	67	0	0	0	100
500pg <i>fzd7</i> CRD + 1.5 ng <i>dv1</i> Δ N 2x DB	20	2	4	10	4	10	20	50	20
500pg <i>fzd7</i> CRD + 1.5ng <i>dv1</i> Δ N 2x VB	30	0	0	0	30	0	0	0	100

***fzd7* CRD is rescued by *dv1* Δ N.** Injecting 1.5 ng of *dv1* Δ N capped RNA does not give a cardiac phenotype. Coinjecting 160 ng *fzd7* CRD with from 750pg –1.5ng of *lacZ* capped RNA gives between 33% and 46% embryos with severe cardia bifida and between 17% and 10% embryos with normal hearts. Coinjecting with *dv1* Δ N capped RNA from 750pg- 1.5ng gives a dose responsive decrease of embryos with severe cardia bifida 25% at 750pg to 7% at 1.25ng and an increase in embryos with a normal heart from 18% at 750pg to 44% at 1.25ng. DB: dorsal blastomeres, VB: ventral blastomeres.

Figure S1:



Cardiac development is independent on the convergent extension movement defects caused by overexpression of *fzd7*. (A, B). *fzd7* full length (250pg) injected into the dorsal blastomeres at 8 cell stage and incubated till stage-32 showing detectable *tnnic* (A) and *nkx2-5* (B) expression in both normal embryos and those with convergent extension movement defects (arrow heads in A and B).